
Evaluating Recent Advances in Breast Cancer Treatment: A Critical Review of the Literature
Introduction Breast cancer remains one of the most prevalent cancers globally and continues to affect millions of women each year. Although improvements in early detection and treatment have contributed to better survival outcomes, breast cancer remains a complex and heterogeneous disease that requires continuous research and innovation. Recent developments have shifted breast cancer treatment towards more precise, personalised, and targeted approaches designed to improve outcomes while reducing unnecessary effects on healthy tissue. Advances in targeted therapies, breast cancer immunotherapy, personalised medicine, genomic testing, and radiation therapy are changing how different breast cancer subtypes are managed. These developments are particularly important for cancers with limited treatment options, including triple-negative breast cancer (TNBC). At the same time, emerging approaches such as the breast cancer vaccine, liquid biopsy, and next-generation targeted therapies are being investigated as potential future strategies. This critical review examines recent developments in breast cancer treatment, focusing on targeted therapies, immunotherapy, personalised medicine, and radiation therapy. It also considers current limitations and emerging directions within breast cancer research. Recent Advances in Breast Cancer Treatment Modern breast cancer treatment increasingly focuses on selecting therapies according to tumour characteristics rather than applying the same treatment strategy to every patient. This shift has been supported by advances in molecular diagnostics, genomic profiling, targeted therapies, and immune-based treatments. The major areas of recent development include: Each approach offers potential benefits, but important limitations remain and require continued investigation. Targeted Therapy in Breast Cancer Targeted therapy breast cancer approaches focus on specific molecules or biological pathways involved in tumour growth and progression. Unlike conventional chemotherapy, which can affect both cancerous and healthy cells, targeted therapies are designed to act more selectively on cancer-related targets. This approach may reduce damage to normal tissue and potentially limit certain treatment-related side effects. HER2-Positive Breast Cancer HER2-positive breast cancer is characterised by overexpression of the HER2 protein. Significant progress has been made in treating this subtype through therapies directed at the HER2 pathway. Agents including trastuzumab, pertuzumab, and T-DM1 have demonstrated benefits in improving survival and reducing recurrence. Research cited in the original review also describes improved overall survival associated with combinations of pertuzumab and trastuzumab in HER2-positive breast cancer. However, resistance to HER2-targeted treatments remains an important challenge. Consequently, ongoing breast cancer research is investigating new treatment combinations and next-generation inhibitors to overcome resistance and improve long-term outcomes. Hormone Receptor-Positive Breast Cancer Hormone receptor-positive breast cancers can be treated using therapies directed towards estrogen and progesterone receptor pathways. Tamoxifen and aromatase inhibitors have traditionally played important roles in treatment. More recently, CDK4/6 inhibitors such as palbociclib and ribociclib have expanded treatment options. Research indicates that combining CDK4/6 inhibitors with endocrine therapy can improve progression-free survival in patients with advanced hormone receptor-positive breast cancer. However, adverse effects, including neutropenia and gastrointestinal problems, require appropriate monitoring. Breast Cancer Immunotherapy Breast cancer immunotherapy has become an important area of research, particularly for triple-negative breast cancer. Immunotherapy works by enhancing the body’s immune response against cancer cells. Triple-negative breast cancer presents particular treatment challenges because it lacks the hormone receptors and HER2 target used in several other breast cancer therapies. Immune Checkpoint Inhibitors Immune checkpoint inhibitors such as pembrolizumab and atezolizumab have demonstrated potential in treating TNBC. These therapies work by blocking proteins that suppress immune responses, allowing immune cells to attack cancer cells more effectively. The original review notes encouraging findings from studies of checkpoint inhibitors in TNBC, including research involving atezolizumab combined with chemotherapy. However, response rates remain variable, highlighting the importance of identifying predictive biomarkers that can determine which patients are most likely to benefit. Therefore, the future development of breast cancer immunotherapy depends not only on discovering new immune-based treatments but also on improving patient selection and understanding mechanisms of treatment response and resistance. Breast Cancer Vaccine Research The breast cancer vaccine is an emerging area of investigation within cancer immunotherapy. Researchers are exploring vaccines designed to stimulate the immune system to recognise and attack breast cancer cells. The original review identifies cancer vaccines as an innovative but still developing strategy. Early-stage trials are investigating whether personalised cancer vaccines could provide additional treatment opportunities, particularly for aggressive or recurrent breast cancers. Unlike established treatment approaches, vaccine-based strategies remain an emerging field. Further clinical research is required to determine their effectiveness, appropriate patient populations, long-term safety, and potential role alongside existing treatments. The development of personalised vaccines could eventually become an important component of precision-based breast cancer treatment, although additional evidence is needed before their broader clinical application. Personalised Medicine in Breast Cancer Treatment Personalised medicine, also referred to as precision medicine, aims to match treatment decisions with the biological characteristics of an individual’s cancer. Breast cancer is highly heterogeneous, meaning that tumours can differ substantially in their molecular characteristics and responses to treatment. Advances in genomic profiling and molecular diagnostics have therefore become increasingly important for treatment selection. Genomic Testing and Biomarkers Genomic testing can help identify characteristics of tumour cells that influence treatment decisions. Tests such as Oncotype DX and MammaPrint assess gene expression and can help estimate recurrence risk and potential benefit from chemotherapy. The original review highlights evidence suggesting that Oncotype DX can identify some patients who may avoid chemotherapy without compromising their prognosis. Such approaches may reduce unnecessary exposure to chemotherapy-related toxicity while supporting more individualised treatment decisions. Liquid Biopsy Liquid biopsy is another developing area of breast cancer research. It involves detecting circulating tumour DNA and other biomarkers in blood samples. Because liquid biopsy is minimally invasive, it may provide opportunities for monitoring tumour progression, detecting recurrence, and understanding changes in tumour biology over time. However, the technology remains under development. Questions concerning sensitivity, specificity, validation, and clinical implementation require further research before its full potential can be established. Advances in Radiation Therapy Radiation therapy remains an important component of breast cancer treatment, particularly for early-stage disease and post-surgical management. Recent advances aim to improve treatment precision, reduce unnecessary exposure to healthy tissues, and shorten treatment duration. Hypofractionated Radiation Therapy Hypofractionated radiation




